MedPath

Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke

Effect of Losartan on Airway Mucociliary Dysfunction in Patients With COPD and Chronic Bronchitis

Phase 4
Terminated
Conditions
COPD
Chronic Bronchitis
Interventions
First Posted Date
2015-04-14
Last Posted Date
2020-08-20
Lead Sponsor
University of Miami
Target Recruit Count
31
Registration Number
NCT02416102
Locations
🇺🇸

University of Miami, Miami, Florida, United States

Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)

Phase 2
Terminated
Conditions
Diabetic Nephropathies
Interventions
Dietary Supplement: Calcitriol
First Posted Date
2015-04-07
Last Posted Date
2017-06-15
Lead Sponsor
Weill Cornell Medical College in Qatar
Target Recruit Count
56
Registration Number
NCT02410005
Locations
🇶🇦

Weill Cornell Medical College in Qatar, Doha, Qatar

🇶🇦

Hamad Medical Corporation, Doha, Qatar

🇺🇸

Weill Cornell Medical College, New York, New York, United States

Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405

Phase 1
Completed
Conditions
Hypertension(HTN)
Interventions
First Posted Date
2015-03-13
Last Posted Date
2015-06-12
Lead Sponsor
Hanmi Pharmaceutical Company Limited
Target Recruit Count
33
Registration Number
NCT02387554
Locations
🇰🇷

Seoul National University Bundang Hospital, Bundang, Gyeonggi, Korea, Republic of

Preventing Sickle Cell Kidney Disease

Phase 2
Terminated
Conditions
Anemia, Sickle Cell
Sickle Cell Disease
Kidney Disease
Proteinuria
Hypertension
Interventions
First Posted Date
2015-02-26
Last Posted Date
2024-04-03
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
1
Registration Number
NCT02373241
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

Comparison of Effects Between Amlodipine and Hydrochlorothiazide in Combination With Losartan on 24-hr Central Blood Pressure in Hypertensive Patients

First Posted Date
2014-11-19
Last Posted Date
2017-03-15
Lead Sponsor
Chong-Jin Kim
Target Recruit Count
231
Registration Number
NCT02294539
Locations
🇰🇷

Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of

Phase 1/2 Prospective Double-Blind Placebo-Controlled Randomized Clinical Trial of Losartan to Treat Grade II & III Hamstring Strains

Phase 1
Terminated
Conditions
Hamstring Injury
Interventions
Drug: Placebo
First Posted Date
2014-10-13
Last Posted Date
2024-05-02
Lead Sponsor
James J. Irrgang
Target Recruit Count
8
Registration Number
NCT02263729
Locations
🇺🇸

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial Hypertension

Phase 3
Completed
Conditions
Arterial Hypertension
Interventions
First Posted Date
2014-09-25
Last Posted Date
2019-05-06
Lead Sponsor
R-Pharm
Target Recruit Count
179
Registration Number
NCT02248961
Locations
🇷🇺

Moscow Health Department "City Clinical Hospital № 81", Moscow, Russian Federation

🇷🇺

St. Petersburg State healthcare Institution "City Hospital number 28" "Maximilianovskaya", St. Petersburg, Russian Federation

🇷🇺

St. Petersburg State Healthcare Institution 'Diagnostic Centre #85', St. Petersburg, Russian Federation

and more 10 locations

Study of High Dosage of Losartan in Comparison to Low Dose of Losartan in Heart Failure Patients

Phase 4
Withdrawn
Conditions
Heart Failure
Interventions
First Posted Date
2014-09-12
Last Posted Date
2018-11-02
Lead Sponsor
Baker Heart and Diabetes Institute
Registration Number
NCT02238457

An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension

Phase 3
Completed
Conditions
Hypertension
Interventions
Drug: Azilsartan Medoxomil High-dose (40 mg)
Drug: Azilsartan Medoxomil Medium-dose (20 mg)
First Posted Date
2014-09-10
Last Posted Date
2025-02-25
Lead Sponsor
Arbor Pharmaceuticals, Inc.
Target Recruit Count
377
Registration Number
NCT02235909
Locations
🇧🇷

Fundação José Luiz Egydio Setúbal, São Paulo, Brazil

🇺🇸

Pioneer Clinical Research, North Miami, Florida, United States

🇺🇸

Georgia Clinical Research, Snellville, Georgia, United States

and more 66 locations

Efficacy and Safety of Losartan in Children With Ig A Nephropathy

Phase 3
Completed
Conditions
Glomerulonephritis, IGA
Interventions
First Posted Date
2014-09-05
Last Posted Date
2018-10-10
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
37
Registration Number
NCT02232776
Locations
🇰🇷

Seoul National University Children's Hospital, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath